The stock may initially trade up on the clinical milestone but face pressure from the dilutive financing. Watch for the closing on August 3 and any pricing discount on the offering. The Phase 1/2 trial initiation is a key pipeline catalyst, but the significant share issuance caps near-term upside.
Price Chart
Executive Summary
Camp4 Therapeutics received Australian regulatory clearance to initiate a Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, triggering a second closing of its September 2025 private placement. The company is eligible to receive up to $50.1 million in gross proceeds by issuing up to 32.7 million shares, with closing expected by August 3, 2026. The clinical milestone is positive but offset by significant dilutive financing.
Key Facts
- Australian TGA and HREC clearance received to initiate Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder
- Regulatory milestone triggers second closing of September 2025 Securities Purchase Agreement
- Company eligible to receive up to $50.1 million in gross proceeds from second closing
- Second closing involves issuance of up to 32,721,172 shares of common stock (or pre-funded warrants)
- Second closing expected on or about August 3, 2026, subject to customary conditions
- Investors committed include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage Capital, Trails Edge, and CURE SYNGAP1
Financial Impact
Up to $50.1M gross proceeds from second closing at an undisclosed price per share, issuing up to 32.7M shares (or pre-funded warrants). The offering size represents approximately 30% of the $164M market cap, implying material dilution.
Risk Factors
- Dilution of approximately 20% of shares outstanding based on current market cap and the up to 32.7M shares issued
- Clinical trial risks for CMP-002 (first-in-human, CNS disorder)
- Potential failure to satisfy remaining closing conditions for the second closing
- Regulatory delays in expanding the trial internationally
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-049661 |
| Exhibit: exhibit991-camp4ctaandpipe.htm | 0001628280-26-049661 |
| Document: 0001628280-26-049661-index-headers.html | 0001628280-26-049661 |
| Document: 0001628280-26-049661-index.html | 0001628280-26-049661 |
| Document: 0001628280-26-049661.txt | 0001628280-26-049661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Press Release | $4.34 $4.03 | ▼ −7.14% | ▼ −6.64% | $3.73 (−13.95%) |
Sep 2, 2026 29d ago | Insider Cluster | $4.49 $4.25 | ▼ −5.35% | ▼ −4.20% | $3.73 (−16.83%) |
Aug 21, 2026 6w ago | Insider Cluster | $4.48 $4.15 | ▲ +7.37% | ▲ +7.84% | $3.73 (+16.64%) |
Aug 13, 2026 7w ago | EFFECT | $4.50 $4.45 | ▼ −1.11% | ▲ +0.85% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Aug 5, 2026 8w ago | Insider Cluster | $4.50 $4.50 | · 0.00% | ▼ −1.21% | $3.73 (−17.01%) |
Jul 27, 2026 9w ago | 8-K | $3.42 $3.45 | ▲ +0.88% | ▼ −0.20% | $3.73 (+9.20%) |
Jun 19, 2026 14w ago | Press Release | $4.20 $4.20 | · 0.00% | ▲ +2.07% | $3.73 (−11.08%) |
Jun 12, 2026 15w ago | 8-K | $3.96 $4.20 | ▲ +6.06% | ▲ +7.44% | $3.73 (−5.69%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.22 $4.14 | ▼ −1.90% | ▼ −2.33% | $3.73 (−11.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access